Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer

Abstract excerpt

BACKGROUND: Gemcitabine (GEM) is used as a first-line therapy for patients diagnosed with any stage of pancreatic cancer (PC); however, patient survival is poor because of GEM resistance. Thus, new approaches to overcome GEM resistance in PC are urgently needed. Here, we aimed to establish an in vivo drug-resistant PC model and identify genes involved in GEM resistance. We focused on one of these factors, CITED4,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hedgehog Signaling Pathway Studies
• Share to Pancreatic and Hepatic Oncology Research
• Share to Protein Degradation and Inhibitors